Docetaxel

多西他赛

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameDocetaxel
Drug Alias NameDocetaxol紫杉萜多西他塞DocetaxelumDTX +[26] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation promotersTubulin depolymerization inhibitors
TargetsTubulin
Therapy Area/IndicationsMetastatic breast cancerHormone-Resistant Prostate NeoplasmsSolid tumours +[45] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungBreast Neoplasms
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungBreast Neoplasms
Original Approved Country/TerritoryEU
Original Approved Date1995/11/27
Country/TerritoryBelgiumCanadaUnited States +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of TromsoBoryung CorpGlaxosmithkline Plc +[17] 
Inactive CompaniesDana-Farber Cancer InstituteNewlink Genetics CoHospira +[49] 
Active IndicationsUrinary Bladder NeoplasmsUrologic NeoplasmsProstatic Neoplasms +[16] 
Inactive IndicationsMetastatic breast cancerHormone-Resistant Prostate NeoplasmsSolid tumours +[29] 

Other Information

ATC CodeL01CD02
Related LinksWikipediaDrugBankKEGG